<p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - 获取免费报告) 的股价在周四的午盘交易中因内部人士卖出活动下跌了 3.9%。该股最低交易价格为 37.47 美元，最后交易价格为 37.2550 美元。在交易中大约有 120,139 股易手，较平均每日交易量 729,320 股下降了 84%。该股此前收盘价为 38.78 美元。</p>
<p>获取 <strong>Harmony Biosciences</strong> 的提醒：</p>
<p>具体来说，首席执行官杰弗里·M·戴诺在 12 月 12 日星期五的交易中出售了 25,933 股该股票。该股票以平均价格 40.11 美元出售，总交易额为 1,040,172.63 美元。此次出售在向 SEC 提交的文件中披露，该文件可通过 SEC 网站获取。</p>
<h2>华尔街分析师观点</h2>
<p>几位分析师对该公司发布了报告。华尔街 Zen 在 12 月 13 日的研究报告中将 Harmony Biosciences 的评级从 “持有” 上调至 “买入”。德意志银行将 Harmony Biosciences 的目标股价从 54.00 美元下调至 36.00 美元，并在 9 月 25 日的报告中对该公司给予 “买入” 评级。Oppenheimer 在 11 月 24 日的报告中重申了 “跑赢大盘” 评级，并将 Harmony Biosciences 的目标价设定为 62.00 美元。瑞穗证券在 12 月 1 日的研究报告中将 Harmony Biosciences 的目标价从 39.00 美元上调至 46.00 美元，并给予该股 “跑赢大盘” 评级。最后，Needham &amp; Company LLC 在 11 月 24 日的研究报告中重申了 “买入” 评级，并将 Harmony Biosciences 的目标价设定为 42.00 美元。一位分析师给予该股 “强烈买入” 评级，七位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股目前的共识评级为 “适度买入”，共识目标价为 45.63 美元。</p>
<p><strong>查看我们关于 Harmony Biosciences 的最新研究报告</strong></p>
<h2>Harmony Biosciences 股价下跌 3.1%</h2>
<p>该股的 50 日移动平均线为 32.73 美元，200 日移动平均线为 33.38 美元。该公司的市值为 21.6 亿美元，市盈率为 11.75，市盈增长比率为 0.49，贝塔值为 0.80。该公司的流动比率为 3.75，速动比率为 3.72，债务股本比率为 0.18。</p>
<p>Harmony Biosciences (NASDAQ:HRMY - 获取免费报告) 最近在 11 月 4 日发布了其财报。该公司报告本季度每股收益为 0.87 美元，低于分析师共识预期的 0.92 美元，差额为 0.05 美元。该公司本季度的收入为 2.3946 亿美元，而分析师预期为 2.2268 亿美元。Harmony Biosciences 的股本回报率为 24.88%，净利润率为 22.50%。研究分析师预测，Harmony Biosciences Holdings, Inc.将在当前财政年度发布 2.43 美元的每股收益。</p>
<h2>对 Harmony Biosciences 的对冲基金观点</h2>
<p>对冲基金最近对该公司的持仓进行了调整。Strs Ohio 在第一季度购买了价值 587,000 美元的 Harmony Biosciences 新头寸。Robeco Institutional Asset Management B.V.在第二季度购买了价值约 1,478,000 美元的 Harmony Biosciences 新股份。Capital Fund Management S.A.在第二季度购买了价值约 1,142,000 美元的 Harmony Biosciences 新股份。CX Institutional 在第二季度将其在 Harmony Biosciences 的持股增加了 166.8%。CX Institutional 目前拥有 207,783 股该公司的股票，价值 6,566,000 美元，此前在上个季度又购买了 129,916 股。最后，Woodline Partners LP 在第一季度购买了价值约 6,035,000 美元的 Harmony Biosciences 新股份。86.23% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Harmony Biosciences 公司简介</h2>
<p>(获取免费报告)</p>
<p>Harmony Biosciences Holdings, Inc.是一家商业阶段的制药公司，专注于开发和商业化针对美国罕见及其他神经系统疾病患者的疗法。该公司提供 WAKIX（匹托利桑），这是一种具有新机制的分子，用于治疗成年嗜睡症患者的过度白天嗜睡。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票比 Harmony Biosciences 更好</li>
<li>什么是空头头寸？如何使用它</li>
<li>3 只便宜的分红股票可以战胜通胀并支付你等待的费用</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>3 只可能在 2026 年扭转局面的新年决议股票</li>
<li>动荡市场中的资产配置策略</li>
<li>大麻股票反弹：幻想还是机会？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Harmony Biosciences 吗？</h2>
<p>在考虑 Harmony Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Harmony Biosciences 并不在名单上。</p>
<p>虽然 Harmony Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HRMY

<p>Harmony Biosciences 的股票（NASDAQ:HRMY）在首席执行官 Jeffrey M. Dayno 出售 25,933 股后下跌了 3.9%。该股票交易最低价为 37.47 美元，交易量显著下降。分析师的评级不一，普遍共识为 “适度买入”，目标价为 45.63 美元。公司报告了低于预期的上一季度收益。对冲基金正在调整在该公司的持仓</p>

<p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report)'s share price dropped 3.9% during mid-day trading on Thursday following insider selling activity. The stock traded as low as $37.47 and last traded at $37.2550. Approximately 120,139 shares traded hands during trading, a decline of 84% from the average daily volume of 729,320 shares. The stock had previously closed at $38.78.</p>
<div class="lb-trans"><p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - 获取免费报告) 的股价在周四的午盘交易中因内部人士卖出活动下跌了 3.9%。该股最低交易价格为 37.47 美元，最后交易价格为 37.2550 美元。在交易中大约有 120,139 股易手，较平均每日交易量 729,320 股下降了 84%。该股此前收盘价为 38.78 美元。</p>
</div><p>Get <strong>Harmony Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Harmony Biosciences</strong> 的提醒：</p>
</div><p>Specifically, CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>具体来说，首席执行官杰弗里·M·戴诺在 12 月 12 日星期五的交易中出售了 25,933 股该股票。该股票以平均价格 40.11 美元出售，总交易额为 1,040,172.63 美元。此次出售在向 SEC 提交的文件中披露，该文件可通过 SEC 网站获取。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several analysts have issued reports on the company. Wall Street Zen raised Harmony Biosciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, December 13th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Harmony Biosciences from $54.00 to $36.00 and set a &#34;buy&#34; rating for the company in a report on Thursday, September 25th. Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $62.00 target price on shares of Harmony Biosciences in a report on Monday, November 24th. Mizuho lifted their target price on shares of Harmony Biosciences from $39.00 to $46.00 and gave the stock an &#34;outperform&#34; rating in a research report on Monday, December 1st. Finally, Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $42.00 price target on shares of Harmony Biosciences in a research report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $45.63.</p>
<div class="lb-trans"><p>几位分析师对该公司发布了报告。华尔街 Zen 在 12 月 13 日的研究报告中将 Harmony Biosciences 的评级从 “持有” 上调至 “买入”。德意志银行将 Harmony Biosciences 的目标股价从 54.00 美元下调至 36.00 美元，并在 9 月 25 日的报告中对该公司给予 “买入” 评级。Oppenheimer 在 11 月 24 日的报告中重申了 “跑赢大盘” 评级，并将 Harmony Biosciences 的目标价设定为 62.00 美元。瑞穗证券在 12 月 1 日的研究报告中将 Harmony Biosciences 的目标价从 39.00 美元上调至 46.00 美元，并给予该股 “跑赢大盘” 评级。最后，Needham &amp; Company LLC 在 11 月 24 日的研究报告中重申了 “买入” 评级，并将 Harmony Biosciences 的目标价设定为 42.00 美元。一位分析师给予该股 “强烈买入” 评级，七位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股目前的共识评级为 “适度买入”，共识目标价为 45.63 美元。</p>
</div><p><strong>View Our Latest Research Report on Harmony Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Harmony Biosciences 的最新研究报告</strong></p>
</div><h2>Harmony Biosciences Stock Down 3.1%</h2>
<div class="lb-trans"><h2>Harmony Biosciences 股价下跌 3.1%</h2>
</div><p>The stock's fifty day moving average is $32.73 and its 200 day moving average is $33.38. The company has a market capitalization of $2.16 billion, a P/E ratio of 11.75, a price-to-earnings-growth ratio of 0.49 and a beta of 0.80. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18.</p>
<div class="lb-trans"><p>该股的 50 日移动平均线为 32.73 美元，200 日移动平均线为 33.38 美元。该公司的市值为 21.6 亿美元，市盈率为 11.75，市盈增长比率为 0.49，贝塔值为 0.80。该公司的流动比率为 3.75，速动比率为 3.72，债务股本比率为 0.18。</p>
</div><p>Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.05). The firm had revenue of $239.46 million for the quarter, compared to analysts' expectations of $222.68 million. Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%. Research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Harmony Biosciences (NASDAQ:HRMY - 获取免费报告) 最近在 11 月 4 日发布了其财报。该公司报告本季度每股收益为 0.87 美元，低于分析师共识预期的 0.92 美元，差额为 0.05 美元。该公司本季度的收入为 2.3946 亿美元，而分析师预期为 2.2268 亿美元。Harmony Biosciences 的股本回报率为 24.88%，净利润率为 22.50%。研究分析师预测，Harmony Biosciences Holdings, Inc.将在当前财政年度发布 2.43 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Harmony Biosciences</h2>
<div class="lb-trans"><h2>对 Harmony Biosciences 的对冲基金观点</h2>
</div><p>Hedge funds have recently made changes to their positions in the business. Strs Ohio purchased a new position in Harmony Biosciences during the 1st quarter valued at $587,000. Robeco Institutional Asset Management B.V. bought a new stake in shares of Harmony Biosciences during the 2nd quarter valued at about $1,478,000. Capital Fund Management S.A. purchased a new position in shares of Harmony Biosciences during the second quarter valued at about $1,142,000. CX Institutional raised its stake in Harmony Biosciences by 166.8% in the second quarter. CX Institutional now owns 207,783 shares of the company's stock worth $6,566,000 after buying an additional 129,916 shares in the last quarter. Finally, Woodline Partners LP purchased a new stake in Harmony Biosciences in the first quarter worth about $6,035,000. 86.23% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。Strs Ohio 在第一季度购买了价值 587,000 美元的 Harmony Biosciences 新头寸。Robeco Institutional Asset Management B.V.在第二季度购买了价值约 1,478,000 美元的 Harmony Biosciences 新股份。Capital Fund Management S.A.在第二季度购买了价值约 1,142,000 美元的 Harmony Biosciences 新股份。CX Institutional 在第二季度将其在 Harmony Biosciences 的持股增加了 166.8%。CX Institutional 目前拥有 207,783 股该公司的股票，价值 6,566,000 美元，此前在上个季度又购买了 129,916 股。最后，Woodline Partners LP 在第一季度购买了价值约 6,035,000 美元的 Harmony Biosciences 新股份。86.23% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Harmony Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Harmony Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.</p>
<div class="lb-trans"><p>Harmony Biosciences Holdings, Inc.是一家商业阶段的制药公司，专注于开发和商业化针对美国罕见及其他神经系统疾病患者的疗法。该公司提供 WAKIX（匹托利桑），这是一种具有新机制的分子，用于治疗成年嗜睡症患者的过度白天嗜睡。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Harmony Biosciences</li>
<li>What is Short Interest? How to Use It</li>
<li>3 Cheap Dividend Stocks That Can Beat Inflation and Pay You to Wait</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>3 New Year’s Resolution Stocks That Could Turn Around in 2026</li>
<li>Asset Allocation Strategies in Volatile Markets</li>
<li>Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Harmony Biosciences 更好</li>
<li>什么是空头头寸？如何使用它</li>
<li>3 只便宜的分红股票可以战胜通胀并支付你等待的费用</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>3 只可能在 2026 年扭转局面的新年决议股票</li>
<li>动荡市场中的资产配置策略</li>
<li>大麻股票反弹：幻想还是机会？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Harmony Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Harmony Biosciences 吗？</h2>
</div><p>Before you consider Harmony Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Harmony Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Harmony Biosciences 并不在名单上。</p>
</div><p>While Harmony Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Harmony Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Harmony Biosciences (NASDAQ:HRMY) 在内部人士抛售后股价下跌 3.9%